[Blood levels of 5-FU and uracil on additional use of uracil in UFT therapy in gastrectomized patients].
Our previous report made it clear that on UFT therapy in the gastrectomized patients reconstructed with Billroth II or various types of esophagojejunostomy, Futraful (FT) kept remained as the non-metabolized in the blood for a long time, but Uracil (Ura) or derived 5-FU merely increased initially. In order to further utilize the remaining FT, additional Ura equivalent to the original composition of UFT was given, once or fractionally at one or two hours after receiving UFT, and consecutive blood levels of FT, Ura and 5-FU were compared with each control without additional use of Ura. When Ura was given one hour after per os UFT, the high blood level of 5-FU lasted another hour, and given at two hours later the concentration curve of 5-FU with two peaks was obtained. The area under curve of 5-FU during the observation period in all the modes of addition reached approximately two-fold against controls. On the other hand, that of Ura increased to 4- to 6-fold compared with each control. Therefore, if Ura is given intermittently on UFT therapy for the gastrectomized patients mentioned above, it would be possible to utilize the remaining FT by inhibiting the degradation of 5-FU derived from it, and Ura might be given in a smaller dose on this application.
Suda
Y
Y
Division of Abdominal Surgery, Saitama Cancer Center Hospital.
Uchida
K
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000097:blood*; D005743:Gastrectomy; D006801:Humans; D008297:Male; D013274:Stomach Neoplasms / Q000097:blood / Q000188:drug therapy / Q000601:surgery; D005641:Tegafur / Q000627:therapeutic use; D014498:Uracil / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use
D005641:Tegafur; D014498:Uracil; D005472:Fluorouracil